Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGB | P11216 | 8/20 | 0.39 |
| ▸ | PYGL | P06737 | 3/20 | 0.39 |
| ▸ | PYGM | P11217 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GBA1 | P04062 | 1/20 | 0.35 |
| ▸ | IDUA | P35475 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4602205 | 1.00 | PYGB (0.39) | PYGBPYGLPYGMLMNAGBA1 | |
| SCHEMBL7074366 | 1.00 | PYGB (0.39) | PYGBPYGLPYGMLMNAGBA1 | |
| SCHEMBL824879 | 1.00 | PYGB (0.39) | PYGBPYGLPYGMLMNAGBA1 | |
| SCHEMBL7107462 | 1.00 | PYGB (0.39) | PYGBPYGLPYGMLMNAGBA1 | |
| SCHEMBL10408121 | 1.00 | PYGB (0.39) | PYGBPYGLPYGMLMNAGBA1 | |
| SCHEMBL7074369 | 1.00 | PYGB (0.39) | PYGBPYGLPYGMLMNAGBA1 | |
| SCHEMBL28664605 | 0.94 | PYGB (0.45) | PYGBPYGLPYGMLMNAGBA1 | |
| SCHEMBL9862851 | 0.94 | PYGB (0.45) | PYGBPYGLPYGMLMNAGBA1 | |
| SCHEMBL1842511 | 0.94 | PYGB (0.45) | PYGBPYGLPYGMLMNAGBA1 | |
| SCHEMBL1842510 | 0.94 | PYGB (0.45) | PYGBPYGLPYGMLMNAGBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1436291-B1 | INDOLIZINES AS KINASE PROTEIN INHIBITORS | AVENTIS PHARMA SA (FR) | 2009-01-14 | — | — | EP | disclosed |
| US-20070238734-A1 | JNK INHIBITORS | SANOLI-AVENTIS (FR) | 2007-10-11 | — | — | US | disclosed |
| US-7148215-B2 | Prodrugs as antihistamines or anticarcinogenic agents | AVENTIS PHARMA S.A. (FR) | 2006-12-12 | — | — | US | disclosed |
| US-20050009831-A1 | Pyrrolo[1,2-a]pyrazine-8-carboxamides are JNK inhibitors, useful as anticarcinogenic agents | AVENTIS PHARMA S.A, (FR) | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238734-A1 | JNK INHIBITORS | MAP3K7, MAPKAPK2, MAPK7 | PYGB 2826/4885PYGL 1253/4885PYGM 3453/4885 |
| US-20050009831-A1 | Pyrrolo[1,2-a]pyrazine-8-carboxamides are JNK inhibitors, useful as anticarcinogenic agents | CNKSR1, ROS1, NRAS | PYGB 4039/4885PYGL 2629/4885PYGM 4689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.